CareDx Reiterates Position that it Does Not Infringe Natera's ‘544 PatentInjunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMapCareDx, Inc. (NASDAQ:CDNA) – The
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular RejectionCardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday’s session after the company reported worse-than-expected quarterly financial results.…